tradingkey.logo
tradingkey.logo

Pharma Mar Receives Positive Opinion From EMA Recommending Approval Of Zepzelca With Atezolizumab

ReutersMar 27, 2026 11:49 AM

- Pharma Mar SA PHMR.MC:

  • RECEIVES POSITIVE OPINION FROM THE EMA'S CHMP RECOMMENDING APPROVAL OF ZEPZELCA® (LURBINECTEDIN) IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ®) FOR TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER

  • RECOMMENDATION IS BASED ON THE RESULTS OF THE IMFORTE PHASE 3 TRIAL

  • LURBINECTEDIN HAS ALSO RECEIVED POSITIVE OPINION FOR DESIGNATION AS ORPHAN DRUG IN SMALL CELL LUNG CANCER

  • PHASE 3 IMFORTE TRIAL, SPONSORED BY ROCHE IN COLLABORATION WITH JAZZ PHARMACEUTICALS

Source text

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI